Enliven Therapeutics Overview

  • Founded
  • 2019
Founded
  • Status
  • Private
  • Employees
  • 22
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $84.9M
Latest Deal Amount
  • Investors
  • 8

Enliven Therapeutics General Information

Description

Developer of oncology therapies designed to improve patients' lives. The company focuses on the discovery and development of next-generation precision oncology therapeutics by combining clinically validated biological targets and industry-leading chemistry to address limitations of existing therapies, providing the healthcare sector with new techniques and helping patients to extend and improve their lives.

Contact Information

Website
www.enliventherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 6200 Lookout Road, First Floor
  • Boulder, CO 80301
  • United States

Enliven Therapeutics Timeline

202020212022
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Enliven Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 19-Jan-2022 $84.9M 00000 00000 Completed Startup
2. Early Stage VC (Series A) 07-Dec-2020 0000 0000 00000 Completed Startup
1. Seed Round 01-Jul-2019 $10M $10M 0000 Completed Stealth
To view Enliven Therapeutics’s complete valuation and funding history, request access »

Enliven Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
Seed 14,507,038 $0.000100 $0.04 $0.71 $0.71 1x $0.71 17.41%
To view Enliven Therapeutics’s complete cap table history, request access »

Enliven Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Sam Kintz Co-Founder, Chief Executive Officer & Board Member
Benjamin Hohl Chief Financial Officer
Anish Patel Co-Founder & Chief Operating Officer
Joe Lyssikatos Ph.D Co-Founder, Chief Scientific Officer & Board Member
Helen Collins MD Chief Medical Officer
To view Enliven Therapeutics’s complete executive team members history, request access »

Enliven Therapeutics Board Members (9)

Name Representing Role Since
Andrew Phillips Ph.D Self Board Member 000 0000
Andrew Schwab 5AM Ventures Board Member 000 0000
Jacob Bauer Self Board Member 000 0000
Joe Lyssikatos Ph.D Enliven Therapeutics Co-Founder, Chief Scientific Officer & Board Member 000 0000
Mika Derynck MD Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Enliven Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enliven Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Boxer Capital Venture Capital Minority 000 0000 000000 0
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
Janus Henderson Investors Asset Manager Minority 000 0000 000000 0
Logos Capital Hedge Fund Minority 000 0000 000000 0
Surveyor Capital Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial